Brought to you by 
Avontec, Biotronik develop drug-coated stents
24 Jul 2003
Executive Summary
Two companies focusing on vascular intervention, Avontec GMBH and medical device firm Biotronik GMBH & Co., are collaborating to develop and market a second-generation drug-eluting stent based on Biotronik's silicon-carbide stent coating and Avontec's new material designed to disrupt the restenosis process that often occurs following angioplasty.
Deal Industry
- Medical Devices
-
Pharmaceuticals
- Drug Delivery
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com